Kontafarma China Holdings (HKSE:01312) EBIT : HK$-28.7 Mil (TTM As of Dec. 2023)

Kontafarma China Holdings EBIT Chart

Kontafarma China Holdings Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EBIT		Get a 7-Day Free Trial					99.56	31.14	-20.86	-94.46	-28.67

Kontafarma China Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															56.83	-58.15	-36.31	50.40	-79.07

Competitive Comparison of Kontafarma China Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kontafarma China Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's EV-to-EBIT falls into.

Kontafarma China Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-28.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings  (HKSE:01312) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kontafarma China Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kontafarma China Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kontafarma China Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kontafarma China Holdings (HKSE:01312) Business Description